The present review focuses on the new therapeutic opportunities offered by the combination of biological drugs, mainly Rituximab, with direct-acting antiviral agents (DAAs).
The dilemma of treating hepatitis C virus-associated cryoglobulinemia
Roccatello D.
Co-first
;Fenoglio R.;Sciascia S.
Last
2019-01-01
Abstract
The present review focuses on the new therapeutic opportunities offered by the combination of biological drugs, mainly Rituximab, with direct-acting antiviral agents (DAAs).
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
10.pdf
Open Access dal 01/10/2020
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
1.2 MB
Formato
Adobe PDF
|
1.2 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
